Russell Investments Group Ltd. grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 167.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,569 shares of the biopharmaceutical company's stock after acquiring an additional 89,287 shares during the quarter. Russell Investments Group Ltd.'s holdings in Amicus Therapeutics were worth $1,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of FOLD. Raymond James Financial Inc. purchased a new position in Amicus Therapeutics during the 4th quarter worth $132,000. Marshall Wace LLP boosted its holdings in shares of Amicus Therapeutics by 254.2% in the 4th quarter. Marshall Wace LLP now owns 72,968 shares of the biopharmaceutical company's stock worth $687,000 after buying an additional 52,368 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Amicus Therapeutics by 82.6% in the 4th quarter. Hsbc Holdings PLC now owns 41,920 shares of the biopharmaceutical company's stock worth $395,000 after buying an additional 18,964 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Amicus Therapeutics by 2.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,368,641 shares of the biopharmaceutical company's stock worth $12,894,000 after buying an additional 26,720 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Amicus Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after buying an additional 187,652 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on FOLD shares. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.
View Our Latest Stock Report on Amicus Therapeutics
Amicus Therapeutics Stock Performance
NASDAQ FOLD traded down $0.03 during trading on Wednesday, hitting $7.85. 5,260,684 shares of the company's stock traded hands, compared to its average volume of 3,573,975. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -65.41 and a beta of 0.55. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $12.65. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The business has a 50 day moving average of $6.66 and a 200-day moving average of $7.09.
Amicus Therapeutics Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
